No evidence for PALB2 methylation in high-grade serous ovarian cancer.

about

Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.Heritable DNA methylation marks associated with susceptibility to breast cancer.

P2860

Q36208014-CA619019-A0D4-41D3-9BC0-86134F4BF29D Q52371352-DE5F60F1-9C68-43F8-978E-639F25B15F86

P2860

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

Item

http://www.wikidata.org/entity/Q36794191

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

@ast

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

@en

type

Item

label

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

@ast

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

@en

prefLabel

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

@ast

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

@en

P1476

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

@en

P2093

David Dl Bowtell

http://www.w3.org/2001/XMLSchema#string

Gillian Mitchell

http://www.w3.org/2001/XMLSchema#string

P2860

Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation

Integrated genomic analyses of ovarian carcinoma

Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer

The implications of heterogeneous DNA methylation for the accurate quantification of methylation

Hallmarks of 'BRCAness' in sporadic cancers

A novel germline PALB2 deletion in Polish breast and ovarian cancer patients

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

PALB2/FANCN: recombining cancer and Fanconi anemia.

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

Origins and molecular pathology of ovarian cancer.

P2888

1757-2215-6-26

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1757-2215-6-26

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Dobrovic

Thomas Mikeska

Australian Ovarian Cancer Study Group

Kathryn Alsop

P577

2013-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236183685

http://www.w3.org/2001/XMLSchema#string

P6179

1028752971

http://www.w3.org/2001/XMLSchema#string

P698

23587053

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

3636006

http://www.w3.org/2001/XMLSchema#string

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

about

P2860

P2860

No evidence for PALB2 methylation in high-grade serous ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P921

P932